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Abstract
Introduction: Dementia pathogenesis begins years before clinical symptom onset,
necessitating the understanding of premorbid risk mechanisms. Here we investigated
potential pathogenic mechanisms by assessing DNA methylation associations with
dementia risk factors in Alzheimer’s disease (AD)–free participants.
Methods: Associations between dementia risk measures (family history, AD genetic
risk score [GRS], and dementia risk scores [combining lifestyle, demographic, and
genetic factors]) and whole-blood DNA methylation were assessed in discovery and
replication samples (n= ~400 to ~5000) fromGeneration Scotland.
Results:ADgenetic risk and twodementia risk scoreswere associatedwithdifferential
methylation. TheGRSassociatedpredominantlywithmethylationdifferences in cisbut
also identified a genomic region implicated in Parkinson disease. Loci associated with
dementia risk scores were enriched for those previously associated with body mass
index and alcohol consumption.
Discussion: Dementia risk measures show widespread association with blood-based
methylation, generating several hypotheses for assessment by future studies.
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alcohol, Alzheimer’s disease, dementia, DNAmethylation, genetic risk score, risk factors
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1 BACKGROUND
The pathophysiology of dementia beginsmany years, possibly decades,
before the emergence of clinical symptoms.1 This long prodromal
phase highlights the need for preventative strategies prior to the
development of irreversible brain damage. As such, understanding
premorbid risk mechanisms is critical. Several approaches to identify
individuals at risk of developing dementia have been devised, including
the summation of genetic risk, in the form of genetic risk scores (GRSs),
the consideration of family history, and the calculation of risk scores,
which incorporate multiple lifestyle, demographic, and genetic risk
factors.2–4
DNA methylation is an epigenetic modification which, in some
contexts, is associated with gene expression variation. Altered gene
expression has been identified in the blood and post-mortem brains
of AD patients,5,6 and post-mortem brain-based studies have iden-
tified associations between DNA methylation and AD and its neu-
ropathological hallmarks.7–9 Blood-based studies, while limited by
small sample sizes, have also found evidence for AD-associatedmethy-
lation differences.10,11 It is not, however, possible to determine from
these studies whether methylation differences precede AD onset,
making them potentially etiologically informative, or whether they
reflect ongoing pathology, compensatory mechanisms and/or treat-
ment effects. Studies that have identified associations between vari-
ation in blood-based DNA methylation and risk factors for demen-
tia (eg, carrying the apolipoprotein E (APOE) ε4 haplotype,12,13 aging,14
and obesity15) suggest that the assessment of methylation in this tis-
sue may yield insights into the pathways and processes that lead to
dementia.
In this study, by assessing associations between multiple measures
of dementia risk and blood-based DNA methylation in AD-free par-
ticipants, we aim to further understand the mechanisms conferring
dementia risk and characterize the role of methylation in these pro-
cesses.
2 METHODS
2.1 Participants
Participants were drawn from the Generation Scotland: Scottish
Family Health Study (GS:SFHS).16,17 The cohort comprises ≈24,000
participants ≥18 years of age at recruitment. At a baseline clinical
appointment, participants were phenotyped for a range of health,
demographic, and lifestyle factors, and provided physical measure-
ments and samples for DNA extraction. GS:SFHS has been granted
ethical approval from the NHS Tayside Committee on Med-
ical Research Ethics, on behalf of the National Health Service
(05/S1401/89), and has Research Tissue Bank Status (15/ES/0040).
GS:SFHS participants provided broad and enduring written informed
consent for biomedical research.
RESEARCH INCONTEXT
1. Systematic review: Several studies have investigated
associations between DNA methylation and individual
dementia risk factors (eg, aging and obesity) but none
has compared multiple risk measures. We compared the
methylation signatures of multifactorial dementia risk
scores, an Alzheimer’s disease (AD) genetic risk score
(GRS), and dementia family history in the two largest
single-cohort blood-basedmethylation samples.
2. Interpretation: In AD-free participants, we identified
methylation associationswith an ADGRS and twomidlife
dementia risk scores, with no overlap between the GRS-
and risk score–associated loci. The GRS analysis iden-
tified loci in cis to significant genome-wide association
study (GWAS) regions and a new putative AD-risk locus,
previously implicated in Parkinson disease. Loci associ-
ated with a midlife dementia risk overlapped with those
associated with alcohol consumption.
3. Future directions: Longitudinal analyses should be per-
formed to assess the pathogenic role of the identified
loci. Analyses to assess the role of the putative novel
dementia-risk locus are warranted.
2.2 Calculation of dementia risk scores
Four dementia risk scores, henceforth referred to as CAIDE1,
CAIDE2,2 Li,3 and Reitz,4 were calculated using data that were col-
lected at GS:SFHS enrollment or obtained through record linkage
(see Figure 1, Supplementary Methods and Table S1 for information
on the contributing variables). To generate each risk score, the con-
tributing variables were scaled and weighted according to the original
studies, and summed. The Reitz score4 was calculated using weight-
ings devised when considering participants with both a “possible” and
“probable” diagnosis of Alzheimer’s disease (AD). Each score was cal-
culated for participants within the appropriate age-range (CAIDE1/2:
39-64 years2; Li:≥60 years3; Reitz:≥65 years).4
2.3 Genotyping and calculation of Alzheimer’s
disease genetic risk score
GS:SFHS genotyping has been described previously18,19 (Sup-
plementary Methods). The AD GRS was calculated using the
lead single-nucleotide polymorphism (SNP) from each of the 26
genome-wide significant loci identified through a meta-analysis
of parental AD and AD20 (Table S2). Each participant’s score was
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F IGURE 1 The variables contributing to each dementia risk score are indicated by filled blue boxes. Abbreviations: APOE ε4, apolipoprotein E
ε4; BMI, bodymass index; HDL, high-density lipoprotein; chol, cholesterol; SBP, systolic blood pressure; T2, type 2;WHR, waist-hip ratio
generated by summing their dosage of each risk allele, weighted by the
corresponding GWAS effect estimate.
2.4 DNA methylation profiling
Whole blood DNAmethylation was profiled using the InfiniumMethy-
lationEPICBeadChip (Illumina Inc.) in two sets ofGS:SFHS participants
at two separate times, leading to a natural discovery (n = 5190) and
replication (n = 4583) design, as described previously21–23 (Supple-
mentary Methods). Discovery and replication sample normalization
was performed separately and the data were converted to M-values.
Participants in the replication sample were unrelated (SNP-based
relatedness<0.05) to each other and/or those in the discovery sample.
A correction for relatedness was applied to the discovery sample
(SupplementaryMethods).
Prior to analyses, poor-performing probes (Supplementary Meth-
ods), sex chromosome probes, participants with unreliable self-report
data, suspected XXY genotype, or self-reported AD (n = 5) were
excluded. The final discovery data set comprised 777,193 loci in
5087 participants; the replication data set comprised 773,860 loci in
4450 participants. Subsequent analyses of the methylation data were
carried out using R versions 3.6.0. or 3.6.1.24
2.5 Epigenome-wide association studies
Epigenome-wide association studies (EWASs) were performed using
linear regression modeling, implemented in limma.25 CpG sites (M-
values) weremodeled as the dependent variable and the dementia risk
measure was the predictor-of-interest. Additional covariates included
in the standardmodels are detailed below:
2.5.1 Discovery sample
CpG site (M-values pre-corrected for relatedness, estimated cell count
proportions, and processing batch) ∼ dementia risk measure + age +
sex + smoking status + pack years + 20 methylation principal compo-
nents
2.5.2 Replication sample
CpG site (M-values) ∼ dementia risk measure+ age + sex + smok-
ing status + pack years + estimated cell count proportions (granulo-
cytes, natural killer cells, B lymphocytes, CD4+ T lymphocytes, and
CD8+ T lymphocytes) + processing batch + 20 methylation principal
components
The variables “smoking status,” “pack years,” and the methy-
lation principal components are explained in the Supplementary
Methods.
A number of sensitivity analyses for the CAIDE1 score were per-
formed inwhich additional covariateswere included one-by-one, using
the same thresholds for categorizing continuous variables as imple-
mented in the risk score. Thesewere bodymass index (BMI;≤30 kg/m2
or>30 kg/m2); systolic blood pressure (SBP;≤140mmHgor>140mm
Hg); total cholesterol (TC; ≤6.5 mmol/L or > 6.5 mmol/L); years
of education (≥10, >6 and <10, or ≤6); self-reported alcohol con-
sumption (log10-transformed (+1) units of alcohol/week), and a DNA
methylation alcohol consumption score derived using the R package
dnamalci.26,27
Limmawas used to calculate empirical Bayes moderated t-statistics
from which P values were obtained. The significance threshold in
the discovery sample was P ≤ 3.6 × 10−8.28 Sites attaining sig-
nificance in the discovery sample were assessed in the replica-
tion sample using a Bonferroni-adjusted threshold of 0.05/no. sites
assessed.
2.6 EWAS meta-analysis
Inverse standarderror-weighted fixedeffectsmeta-analyses of thedis-
covery and replication EWAS results were performed using METAL.29
Sites attaining a meta-analysis P ≤ 3.6 × 10−8 were considered
significant.
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2.7 Identification of differentially methylated
regions
Differentially methylated regions (DMRs) were identified using the
dmrff.meta function in dmrff.30 DMRs were defined as regions con-
taining 2 to 30 sites with consistent direction of effect and EWAS
meta-analysis P values ≤.05 separated by ≤500 bp. DMRs with
Bonferroni-adjusted P values≤.05 were declared significant.
2.8 EWAS and GWAS catalog look-ups
The GWAS Catalog v1.0.2. was downloaded from https://www.ebi.
ac.uk/gwas/docs/file-downloads (December 16, 2019)34 and queried
using gene names annotated to probes containing differentiallymethy-
lated positions (DMPs) identified in the meta-analysis (meta-DMPs)
for the phenotype-of-interest. GWAS traits enriched for association
(P ≤ 1 × 10−5) with genes containing meta-DMPs were identified
using Fisher’s exact test. Enrichment was declared significant when P
≤ 1.26× 10−5 (0.05/3980 traits assessed).
The EWAS Catalog was downloaded from http://www.ewascatalog.
org/ (03/07/19)35 and queried using the significant DMPs probe IDs.
EWAS traits enriched for association (P ≤ 1 × 10−5) with meta-DMPs
were identified using Fisher’s exact test. Enrichment was declared sig-
nificant when P≤ 3.31× 10−4 (0.05/151 traits assessed).
2.9 Gene ontology/KEGG pathway analyses
Gene ontology (GO) and KEGG pathway analyses were implemented
using a modified version of the missMethyl gometh function31 (Sup-
plementary Methods). The target list comprised probes showing sug-
gestive association with the phenotype-of-interest (P ≤ 1 × 10−5)
in the EWAS or DMR analysis, and the gene universe included all
probes in the analyses. Enrichment was assessed using a hyper-
geometric test, accounting for the bias arising from the variation
in the number of probes per gene. Significance thresholds of P ≤
2.20×10−6 andP≤1.48×10−4 were applied to allow for aBonferroni-
correction for the22,750GOterms and337KEGGpathways assessed,
respectively.
2.10 Identification of meQTLs
Methylation quantitative trait loci (meQTLs) for the AD GRS-
associated DMPs were identified using the discovery sample. The
quality control, normalization, and pre-correction of the data prior
to the meQTL analyses have been described previously32 (Supple-
mentary Methods). The resulting residuals were inverse-rank normal
transformed and entered as the dependent variable in simple linear
model GWASs to identify meQTLs. GWASs were implemented using
REGSCAN v0.5.33 SNPs that were associated with a DMP with P ≤
5× 10−8/49 (Bonferroni correction for the 49DMPs for whichmeQTL
results were available), an info score ≥0.8, and had aMAF> 0.01 were
declared to bemeQTLs.
Where ameta-DMP associated with ADGRS harbored a SNP at the
CpG site, linkage disequilibriumbetween theCpGSNP and the nearest
SNP contributing to the GRS was assessed using the LDpair Tool using
data from the British in England and Scotland (GBR) population (https:
//ldlink.nci.nih.gov/?tab=ldpair; June 09, 2020).36
3 RESULTS
3.1 Epigenome-wide asssociation study sample
demographics
Participant numbers and sample demographic information are shown
in Table S3.
3.2 Genetic risk for Alzheimer’s disease
3.2.1 Identification of differentially methylated
positions
An epigenome-wide association study (EWAS) of the Alzheimer’s dis-
ease (AD) genetic risk score (GRS) identified 32 differentially methy-
lated positions (DMPs) in the discovery sample (1.06 × 10−30 ≤P≤
2.22 × 10−8; Table S4). Of these, 31 showed replicated association
(1.07 × 10−30 ≤ P ≤ 8.33 × 10−4; Table S5). Meta-analysis of the dis-
covery and replication samples identified 68DMPs (6.15× 10−48 ≤ P≤
3.45× 10−8; Table 1; Table S6; Figure 2).
Sixty-one of the 68 meta-DMPs were located within 18 of the
26 genome-wide association study (GWAS) loci used to produce the
GRS,20 with six of the remaining seven being located within 30 kb of
one. Four of the associated CpGs have a single nucleotide polymor-
phism (SNP) at the CpG site. Density plots of the signal at these sites
indicated a potential SNP effect on methylation at three of the CpGs
(Figure S1). All three of these SNPs are in high linkage disequilibrium
with the nearest SNP included in the GRS (D’ = 1 for cg02887598
and cg16618979, and D’ = 0.64 for cg12568536). Formal methylation
quantitative trait loci (meQTL) analysis could be performed for 49/68
DMPs: of these, 48 were associated in cis but not trans, with genetic
variants located in the GWAS loci.20 Methylation at the remaining
DMP, cg14354618, which is not locatedwithin or in proximity (<30 kb)
to aGWAS locus,was associated in transwith genetic variationon chro-
mosome 19 (chr19: 868083-1188756; hg19/GRCh37), which overlaps
a GWAS locus.20
There was no overlap between the meta-DMPs identified as being
associated with the CAIDE1 score and the GRS. To explore the rea-
son for this lack of overlap, the Pearson correlation coefficient was
calculated between the two scores. This was small and non-significant
(r=−.018, P= .326).
Querying the GWAS catalog34 with the 34 gene names annotated
to the 68 meta-DMPs unsurprisingly identified many terms related to
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TABLE 1 Top 20DMPs associated with the ADGRS in ameta-analysis of the discovery and replication samples
ID Chr. BP
a
Gene symbol Effect SE P
cg10757760 2 127893054 0.0568 0.0039 6.15× 10−48
cg04441687 11 85869322 0.0586 0.0041 1.12× 10−46
cg26631131 19 45240591 0.0385 0.0029 1.56× 10−39
cg02887598 2 127841945 BIN1 −0.0986 0.0085 2.51× 10−31
cg19116668 7 99932089 PMS2L1 0.049 0.0051 1.54× 10−21
cg18959616 11 85814918 0.0656 0.0072 5.85× 10−20
cg02521229 11 60019236 0.0658 0.0073 1.61× 10−19
cg03579757 7 100091793 NYAP1 0.0342 0.0038 2.33× 10−19
cg16618979 7 143108841 AC092214.10 0.0974 0.0109 5.11× 10−19
cg03526776 6 41159608 TREML2 −0.0402 0.0045 7.06× 10−19
cg11461311 2 127782614 RP11-521O16.1;RP11-521O16.2 0.0321 0.0036 1.31× 10−18
cg00436254 2 127862614 BIN1 0.0256 0.003 6.76× 10−18
cg06750524 19 45409955 APOE 0.05 0.0059 2.18× 10−17
cg23423086 11 85856245 −0.0365 0.0043 2.37× 10−17
cg22906224 7 99728672 AC073842.19 −0.0392 0.0047 3.55× 10−17
cg05908241 7 143109367 AC092214.10 0.0283 0.0035 6.62× 10−16
cg17830204 7 99819110 GATS;PVRIG;STAG3;AC005071.1 0.0308 0.0039 4.78× 10−15
cg19590598 2 127782813 RP11-521O16.1;RP11-521O16.2 0.0282 0.0036 5.22× 10−15
cg08871934 10 11720283 −0.0343 0.0044 9.59× 10−15
cg09555818 19 45449301 APOC2;APOC4 −0.0498 0.0065 1.24× 10−14
Abbreviations: BP, base position; Chr., chromosome; SE, standard error, DMP; differentially methylated position; GRS, genetic risk score.
aBase position in genome assembly hg19/GRCh37.
F IGURE 2 Manhattan plot showing the results of the epigenome-wide association study (EWAS) meta-analysis of the Alzheimer’s disease
(AD) genetic risk score (GRS), and the positions of differentially methylated regions (DMRs) identified in ameta-DMR analysis. Each point
represents one of the 772,453 loci included in the EWASmeta-analysis, with the point’s position being determined by genomic position (x-axis)
and significance in the EWASmeta-analysis (–log10 P value; y-axis). Sites attaining genome-wide significance (P≤ 3.6× 10−8) are indicated in red
and those that are involved in a significant DMR (Bonferroni-correct P≤ .05) are indicated in blue. The locations of DMRs are further indicated by
vertical blue lines. The solid horizontal line is the threshold for genome-wide significance (P≤ 3.6× 10−8) and the dashed line indicates a
suggestive significance threshold (P≤ 1× 10−5)
AD and its neuropathological hallmarks (Table S7), themost significant
being “AD or family history of AD” (P = 1.77 × 10−27). No significant
enrichment was identified when querying the EWAS catalog; however,
this catalogue comprises results from studies using the 450K array on
which only 30/68meta-DMPsweremeasured.
3.2.2 Identification of differentially methylated
regions
The differentially methylated region (DMR) meta-analysis identified
18 significant DMRs comprising 41 CpGs, of which 20 were identified
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TABLE 2 GO terms showing significant enrichment for probes
wheremethylation is associated the ADGRS
Ontology Term Proportiona P
BP Amyloid beta formation 6/34 3.68× 10-10
BP Negative regulation of
amyloid precursor protein
catabolic process
5/16 4.62× 10-10
BP Amyloid precursor protein
catabolic process
6/44 1.89× 10-9
BP Amyloid-betametabolic
process
6/47 2.88× 10-9
BP Regulation of amyloid-beta
formation
5/28 1.12× 10-8
BP Amyloid precursor protein
metabolic process
6/63 1.66× 10-8
CC Protein-lipid complex 6/39 2.53× 10-8
BP Regulation of amyloid
precursor protein
catabolic process
5/35 3.52× 10-8
BP Negative regulation of
amyloid-beta formation
4/13 3.79× 10-8
BP Reverse cholesterol
transport
4/20 8.38× 10-8
BP Protein-lipid complex
subunit organization
6/49 1.38× 10-7
CC High-density lipoprotein
particle
5/26 2.42× 10-7
BP Chylomicron remnant
clearance
3/9 1.12× 10-6
BP Triglyceride-rich lipoprotein
particle clearance
3/9 1.12× 10-6
BP Protein-lipid complex
assembly
6/32 1.13× 10-6
CC Plasma lipoprotein particle 6/37 1.34× 10-6
CC Lipoprotein particle 5/37 1.34× 10-6
BP Very-low-density lipoprotein
particle remodeling
3/12 2.10× 10-6
Abbreviations: BP, biological process; CC, cellular component; GRS, genetic
risk score; GO, gene ontology.
aNumber of significant target list-associated Entrez IDs associatedwith the
gene ontology term/total number of Entrez IDs associated with the GO
term. The target list comprised probes that met a nominal threshold for
association with the ADGRS of P≤ 1× 10−5
by the meta-EWAS (Table S8; Figure 2). Seventeen of the DMRs over-
lap with loci that were in the GWAS,20 and the 18th is located <7 kb
from the nearest GWAS locus. The longest DMR spans a 302 bp region
≈13.7 kb upstream of BIN1, whereas the most significant spans a
199 bp region ≈22.8 kb downstream of BIN1. Both show increased
methylation with increased GRS.
Gene ontology (GO) analysis using the combined DMP and DMR
results identified 18 terms, themost significant of whichwas “amyloid-
beta formation” (P= 3.68 × 10−10; Table 2). No significant KEGG path-
ways were identified.
3.3 Mid-life dementia risk scores
The CAIDE1 and CAIDE2 risk scores assess the risk of developing
dementia in20years’ time in individuals 39 to64yearsof age.2 CAIDE2
takes into account the same risk factors as CAIDE1 (with different
weightings) and also considers apolipoprotein E (APOE) ε4 carrier status.
3.3.1 Identification of differentially methylated
positions
An EWAS of the CAIDE1 score in the discovery sample identified 76
DMPs (3.29 × 10−20 ≤P≤ 3.49 × 10−8; Table S9), of which 65 repli-
cated (7.76× 10−18 ≤ P≤ 6.48× 10−4; Table S10).Meta-analysis of the
discovery and replication samples identified 227 DMPs (1.20 × 10−29
≤ P≤ 3.58× 10−8; Figure 3; Table 3; Table S11).
An EWAS of the CAIDE2 score in the discovery sample identified 18
DMPs (1.96 × 10−17 ≤P≤ 3.24 × 10−8; Table S12), of which 17 repli-
cated (4.91× 10−12 ≤ P≤ 2.01× 10−3; Table S13).Meta-analysis of the
discovery and replication samples identified 59 DMPs (3.56 × 10−22 ≤
P≤3.21×10−8; Table S14). Fifty-four of theCAIDE2meta-DMPswere
also identified by the CAIDE1meta-analysis; given this overlap, subse-
quent analyses focus on CAIDE1.
TheCAIDE1-associatedmeta-DMPswere exploredusing theEWAS
and GWAS catalogs.34 Significant enrichment was identified for 16
EWAS traits/conditions, with “Body mass index [BMI]” being the most
significantly enriched (P = 2.96 × 10−118; Table S15). Two alcohol-
related traits: “alcohol consumption per day” (P = 9.70 × 10−29) and
“gamma-glutamyl transferase” (P = 8.55 × 10−25) also showed enrich-
ment. GWAS catalog enrichment analysis identified only one signifi-
cant term, “Eosinophil counts” (P= 4.97× 10−8).
Sensitivity analyses
The extent to which the BMI component of the CAIDE1 score drives
the observed CAIDE1 associations was assessed by performing an
EWASmeta-analysis inwhichBMIwas includedas anadditional covari-
ate. Co-varying for BMI resulted in only 11 of the original 227 meta-
DMPs remaining significant (Table S11), with the correlation between
the effect estimates for all sites between the two analyses being
r = 0.745 (95% confidence interval (CI) = 0.744 to 0.746). Com-
paredwith BMI, co-varying for other components of the CAIDE1 score
resulted in a larger numbers of CAIDE1 meta-DMPs remaining signifi-
cant (SBP: 94/227; TC: 190/227; education: 221/227; Table S11); cor-
relations with the effect estimates of the original analysis were higher
(SBP: r=0.815, 95%CI=0.815 to 0.816; TC: r=0.938, 95%CI=0.937
to 0.938); education: r= 0.990, 95%CI= 0.990 to 0.990).
Assessment of the involvement of alcohol consumption in the CAIDE1
EWAS results
Twenty-four of the 88 meta-DMPs that are represented on the 450K
array, including the most significant DMP, cg06690548, have previ-
ously been associated with alcohol consumption (P ≤ 1 × 10−5).26
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F IGURE 3 Manhattan plot showing the results of the epigenome-wide association study (EWAS) meta-analysis of the CAIDE1 dementia risk
score and the positions of differentially methylated regions (DMRs) identified in ameta-DMR analysis. Each point represents one of the 772,453
loci included in the EWASmeta-analysis, with the point’s position being determined by genomic position (x-axis) and significance in the EWAS
meta-analysis (–log10 P value; y-axis). Sites attaining genome-wide significance (P≤ 3.6× 10−8) are indicated in red and those that are involved in a
significant DMR (Bonferroni-correct P≤ .05) are indicated in blue. The locations of DMRs are further indicated by vertical blue lines. The solid
horizontal line is the threshold for genome-wide significance (P≤ 3.6× 10−8) and the dashed line indicates a suggestive significance threshold (P≤
1× 10−5)
TABLE 3 Top 20DMPs associated with the CAIDE1 risk score in ameta-analysis of the discovery and replication samples
ID Chr. BP Gene symbol Direction effect SE P
cg06690548 4 139162808 SLC7A11 – −0.0766 0.0068 1.20× 10-29
cg19758958 11 62319222 AHNAK – −0.0256 0.0024 4.22× 10-27
cg11024682 17 17730094 SREBF1 ++ 0.026 0.0025 5.31× 10-26
cg14476101 1 120255992 PHGDH – −0.0391 0.0039 1.14× 10-23
cg00574958 11 68607622 CPT1A – −0.0413 0.0043 8.30× 10-22
cg06500161 21 43656587 ABCG1 ++ 0.0225 0.0024 2.10× 10-21
cg19693031 1 145441552 TXNIP – −0.0369 0.004 8.74× 10-21
cg22699725 1 207242586 PFKFB2 ++ 0.0275 0.003 6.89× 10-20
cg00683922 1 207242569 PFKFB2 ++ 0.0272 0.003 2.70× 10-19
cg05325763 11 68607719 CPT1A – −0.0394 0.0044 2.90× 10-19
cg22976567 1 156074182 LMNA – −0.026 0.0029 7.06× 10-19
cg02715788 8 119974400 – −0.0225 0.0026 4.44× 10-18
cg18120259 6 43894639 LOC100132354 – −0.0209 0.0024 4.49× 10-18
cg11376147 11 57261198 SLC43A1 – −0.0236 0.0028 2.98× 10-17
cg00163198 11 130767760 SNX19 ++ 0.0237 0.0028 4.89× 10-17
cg16246545 1 120255941 PHGDH – −0.0255 0.003 5.16× 10-17
cg01270753 9 101944336 RP11-96L7.2 – −0.034 0.0041 5.27× 10-17
cg08857797 17 40927699 VPS25 ++ 0.0236 0.0028 5.86× 10-17
cg16740586 21 43655919 ABCG1 ++ 0.0243 0.0029 7.52× 10-17
cg26457483 1 120256112 PHGDH – −0.0308 0.0037 1.76× 10-16
Abbreviations: BP, base position; Chr., chromosome; SE, standard error; DMP, differentially methylated position.
aBase position in genome assembly hg19/GRCh37.
Similarly, an EWAS meta-analysis of self-reported alcohol consump-
tion in our methylation sample identified 5599 DMPs at a suggestive
threshold of P ≤ 1 × 10−5 (unpublished data, Clarke et al.); of these, 49
show a significant association with CAIDE1with a consistent direction
of effect. This overlap is highly significant (P< 2× 10−16).
Because alcohol consumption showed a small but significant cor-
relation with CAIDE1 score (r = 0.091; 95% CI = 0.065 to 0.118;
P = 2.60 × 10−11), the potential for alcohol consumption to drive the
observed associations between CAIDE1 and DNA methylation was
assessed by including alcohol consumptionmeasured by (1) self-report
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or (2) a polyepigenetic risk score26,27 as an additional covariate in the
CAIDE1 EWAS. Neither measure of alcohol consumption resulted in a
substantial change in effect estimates (self-reported: r = 0.948, 95%
CI=0.948 to 0.948;DNAmethylation score: r=0.993, 95%CI=0.993
to 0.993), with 166 and 191 of the 227 CAIDE1meta-DMPs remaining
significant after the inclusion of the self-reported and DNA methyla-
tion score coefficients, respectively (Table S11).
3.3.2 Identification of differentially methylated
regions
The DMR meta-analysis of the discovery and replication samples
identified 57 CAIDE1-associated DMRs (all Bonferroni-adjusted
P < 0.044; Table S16), each comprising two to seven CpGs. In total,
the 57 DMRs involve 179 sites, of which 35 were significant in the
EWAS meta-analysis. The most significant DMR (Bonferroni-adjusted
P = 1.67 × 10−20) comprises four hypomethylated CpGs spanning
a 115 bp intronic region of CPT1A (chr11: 68607622-68607737;
hg19/GRCh37). The longest DMR spans a 1.1 kb intronic region of
JARID2 (chr6: 15504844-15505949; hg19/GRCh37).
GO and KEGG pathway analyses found no enrichment for biologi-
cal processes or pathways among the CAIDE1DMP or DMRCpG sites
(min. PGO= 8.46× 10−4; minutes. PKEGG= 3.51× 10−3).
3.4 Other measures of dementia risk
Theothermeasuresof dementia risk assessedwere (1) dementia family
history (FH) and (2) two late-life dementia risk scores that predict the
risk of developing dementia in those older than60or 65 years of age.3,4
EWASs of the discovery sample (minimum (min). PFH= 8.47 × 10−7;
min. PLi= 3.91 × 10−8; min PReitz= 1.58 × 10−6), meta-EWASs
of the discovery and replication samples (min. PFH= 1.15 × 10−6;
min. PLi= 1.80 × 10−6; min. PReitz= 8.99 × 10−7), and DMR analy-
ses (min. Bonferroni-adjusted PFH= 0.439; min. Bonferroni-adjusted
PLi= 0.208; min. Bonferroni-adjusted PReitz= 1) failed to identify any
significant associations.
4 DISCUSSION
We have assessed DNA methylation associations with a range of
dementia risk measures in large discovery and replication samples
comprising Alzheimer’s disease (AD)-free participants, and we report
multiple loci as being associatedwith ADgenetic risk and twomultifac-
torial mid-life risk scores for dementia.
All but one of the loci associated with the AD genetic risk score
(GRS) were locatedwithin 30 kb of the genome-wide association study
(GWAS) loci used to derive the GRS,20 with methylation quantitative
trait loci (meQTL) analysis supporting involvement of cismeQTLs. Only
one differentially methylated position (DMP), cg14354618 on chro-
mosome 11, was an exception to this pattern, being associated with
trans meQTLs in a GWAS risk locus on chromosome 19. cg14354618
is located in a CpG island in AP001979.1. Genetic variation annotated
toAP001979.1 has been associatedwithParkinson’s disease,37,38 body
fat percentage,39 and sugar consumption40 but has not been associ-
ated with AD in large-scale GWASs.41,42 There is a degree of over-
lap between the clinical features and pathologies associated with AD
and Parkinson’s disease, with certain genetic variants being associated
with both.43,44 Moreover, obesity and hyperglycemia have been impli-
cated as dementia risk factors.45 Taken together, these findings sug-
gest this locus to be a plausible AD-risk locus, which warrants further
investigation.
Considering both the meta-DMP and differentially methylated
region (DMR) results, two regions harbor a large number of AD
GRS-associated sites. These regions contain (1) BIN1 and (2) PVRL2,
APOE, APOC4, and APOC2 (henceforth referred to as the APOE locus).
The APOE locus has not been identified previously by brain-based
epigenome-wide association studies (EWASs) of ADneuropathological
hallmarks7,46 or a blood-based AD case-control EWAS44; larger sam-
ples might be required to detect association between methylation at
this locus and AD.
In contrast, several studies have identified altered methylation
of BIN1 in AD patients or in association with AD neuropathological
hallmarks.7,47,48 These findings are of particular interest, as altered
BIN1brain expression has been reported inAD49–51 andDNAmethyla-
tion has been suggested to regulate BIN1’s expression.52 We identified
a mixture of hyper- and hypomethylation in the upstream region and
gene body and hypermethylation in the downstream region. Although
none of the identified sites directly replicated those identified by
previous studies, it is noteworthy that one of our hypermethylated
meta-DMPs (cg18813565) is located only 31 bp from a site (that failed
our quality control) at which increased methylation in the dorsolateral
prefrontal cortex has been associated with neuritic plaque burden and
AD diagnosis.47 Moreover, this site contributes to a hypermethylated
DMR that spans a 199 bp region located ≈23 kb downstream of BIN1.
This region overlaps with non-coding RNAs, RP11-521O16.1, and
RP11-521O16.2, suggesting the possibility that alteredmethylation of
these non-coding RNAs might alter BIN1 expression. This hypothesis
should be assessed by future studies.
The CAIDE1 risk score is a composite score formed by theweighted
summation of age, sex, body mass index (BMI), years in education, sys-
tolic blood pressure, and total cholesterol.2 It is designed for the pre-
dictionof dementia in20years’ time in individuals 39 to64years of age,
which it does with an area under the curve of 0.77 (95% confidernce
interval 0.71 to 0.83). Because age and sex were covariates in our
analytical models, the differential methylation observed in this study
reflects the modifiable “lifestyle” components of the score. Our anal-
yses revealed BMI to be the primary driver of the CAIDE1-associated
methylation differences.We identified significant overlap between the
sites associated with CAIDE1 and those that have been associated
previously with alcohol consumption. Strikingly, the most significant
CpG in our analysis of CAIDE1 was also the most significant CpG in a
recent Generation Scotland: Scottish Family Health Study (GS:SFHS)
alcohol consumption EWAS (unpublished data, Clarke et al.). Although
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alcohol consumption was significantly correlated with CAIDE1 score,
it could not account for the CAIDE1-associated differences in methy-
lation. This finding is of interest in light of the observed associations
between excessive alcohol consumption and dementia risk.53 Our find-
ings suggest that the risk factors contributing to the CAIDE1 score and
alcohol consumption might confer risk for dementia via independent
effects on common pathways.
The loci implicated by our analyses of the AD GRS and the CAIDE1
score did not overlap, and they did not implicate common genes. In
keeping with this, the correlation between the scores was small and
non-significant. This lack of concordance might be attributable to dif-
ferences in the methodology used to create the scores: although the
CAIDE1 score was trained using a sample comprising mixed demen-
tia cases (of which ≈75% were diagnosed with AD),2 the AD GRS
was devised using a sample comprising AD and proxy AD cases.20
Moreover, the CAIDE 1 score predominantly comprises cardiovascu-
lar risk factors for dementia, meaning that it is likely to identify a sub-
population of those at risk for dementia.
Wedid not observe anyDNAmethylation associationswithAD fam-
ily history (FH) or two late-life dementia risk scores. The lack of asso-
ciations with AD FH is somewhat surprising, as this has been shown
previously to be a good AD proxy-phenotype.20 Our failure to observe
significant associations for these traits may reflect a lack of statistical
power, particularly as the samples available for the late-life dementia
risk scores were relatively small.
It is important to note some additional strengths and limitations to
our study. Although it would clearly be desirable to study DNAmethy-
lation in brain tissue, growing evidence highlights the contribution of
systemic factors todementia pathogenesis.54 Thusmethylation studies
in the blood are necessary to provide a holistic characterization of the
processes that contribute to dementia development. Moreover, pro-
filing blood methylation permits both longitudinal analyses to charac-
terize the dynamic processes underlying dementia pathogenesis and
biomarker identification.
An important limitation of our study is that the use of a cross-
sectional design means that causal inferences cannot be drawn. A
corollary of this is that it is difficult to determine whether the methy-
lation differences assessed play a causal role in the development of
dementia. In some cases, causal inference analyses to assess rela-
tionships with important intermediary variables such as cognitive
ability and cognitive decline together with Mendelian randomization
may help delineate likely causality; future studies should assess this
possibility.
Ultimately, the longitudinal assessment of cognitive decline and the
development of dementia will also be necessary to address questions
about causation. Moreover, the availability of longitudinal data would
also permit the development of an epigenetic (and potentially a multi-
factorial genetic, epigenetic, and lifestyle factors) predictor of demen-
tia. An important conceptual issue that must be considered when
attempting to determine causality from longitudinal data is that that
the pathogenesis of dementia is itself a gradual process involving quan-
titative changes in multiple biological systems, which eventually result
in the binary diagnosis of dementia. As such, it might not be possible to
strictly delineate the temporal relationship between risk factors, their
biological correlates and the onset of dementia. Instead, the identifi-
cation of co-occurring processes might yield experimentally testable
hypotheses. An additional factor to consider is that the non-genetic
risk factors that contribute to the scores assessed are themselves only
associated with the development of dementia and do not necessarily
play a causal role. Future studies that aim to delineate the causal con-
tribution of these factors to dementia will facilitate the development
of risk scores whose primary purpose is for use in the investigation of
pathogenic mechanisms.
Other limitations concern the quality of the variables used in the
dementia risk scores: self-reporting may have resulted in errors, and
the blood samples used for cholesterol measurements were not taken
at a consistent time of day or after a consistent fasting length. Fur-
thermore, we considered only a sub-set of putative dementia risk fac-
tors. The demographic and lifestyle risk factors considered in this study
were selected due to their involvement in validated composite risk
scores;2–4 however, it would be of interest to examine DNA methy-
lation associations of other well-supported dementia risk factors in
future studies.
Here we present the first comprehensive characterization of
associations between blood DNA methylation and dementia risk,
performed in the largest single-cohort methylation samples col-
lected to date. We identify several CpGs where methylation is
associated with dementia risk measures and identify a putative
novel AD risk locus. Our findings suggest a number of hypotheses
for assessment by future studies, which should include longitudi-
nal assessments of the causal nature of methylation in dementia
pathogenesis.
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